The results Grail presented as a talk at ESMO are fairly similar to those they presented in somewhat less detail at conferences earlier in the year (AACR and AS

The results Grail presented as a talk at ESMO are fairly similar to those they presented in somewhat less detail at conferences earlier in the year (AACR and ASCO). For those who are interested in a deeper dive on this technology, its potential limitations, and its potential benefits, I wrote up a three-part series earlier this year breaking down recent advances in liquid-biopsy-based cancer detection: Part I: regarding tumor fraction (this goes into depth about the stage I limitations noted by other commenters) https://ihaque.org/posts/2019/07/02/early-detection-mid-2019-part-1/ https://ihaque.org/posts/2019/07/02/early-detection-mid-2019... Part II: technical advances from Grail (the authors here) and Guardant (one of their main commercial competitors) https://ihaque.org/posts/2019/07/08/early-detection-mid-2019-part-2/ https://ihaque.org/posts/2019/07/08/early-detection-mid-2019... Part III: clinical performance and economics - integrating the sensitivity and specificity numbers with a simple model for important clinical parameters like adherence (how many people prescribed to take the test actually do), and cost: https://ihaque.org/posts/2019/08/18/early-detection-mid-2019-part-3/ https://ihaque.org/posts/2019/08/18/early-detection-mid-2019... Disclaimer: I'm the former CSO of a competing company, but I no longer work in this space.